OncoMed receives vantictumab patent


OncoMed Pharmaceuticals (OMED) says the U.S. Patent office has issued a patent related to the way vantictumab treats cancer.

Vantictumab is a Wnt pathway inhibitor and is currently in Phase 1 clinicals.

"The issuance of this patent further validates the novelty of this promising antibody and the innovative nature of OncoMed's ongoing discovery programs," CEO Paul Hastings says. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs